ANZBMS-IFMRS-JSBMR 2017*
Chairs: Michaela Kneissel & T. Jack Martin
Tram2 is a novel genetic determinant of bone mass and strength (#28)
4:00 PM
Mutations in MAP3K7 and TAB2 cause a distinct autosomal dominant form of frontometaphyseal dysplasia through a gain-of-function mechanism (#29)
4:20 PM
Anti-sclerostin antibody treatment prevents myeloma bone disease and increases bone strength (#30)
4:40 PM
The ability of structural deterioration to predict fracture is independent of bone mineral density status: the OFELY study (#31)
5:00 PM
Fracture associated mortality - how much is due to the fracture versus co-morbidity: the 45 and up study (#32)
5:20 PM